Avraham Pharmaceuticals announced the commencement of a Phase 2 clinical trial to evaluate the safety and efficacy of its ladostigil drug in patients diagnosed with mild cognitive impairment (MCI). MCI is a syndrome defined as an intermediate stage between the expected cognitive decline of normal aging and the more pronounced decline of dementia. The 36-month trial will include at least 200 patients in 16 centers in Europe and Israel. In parallel, the company has also completed the enrollment of 200 patients in a Phase 2 trial of ladostigil for the treatment of mild to moderate Alzheimer’s disease. Founded in 2010, Avraham Pharmaceuticals has raised more than $12 million.